宫颈癌肉瘤一例并文献复习

doi:10.12280/gjfckx.20240193

摘要/Abstract

摘要：

宫颈癌肉瘤（cervical carcinosarcoma）是一种由恶性的上皮组织和间质成分组成的恶性肿瘤，患者通常以不规则阴道出血、流液就诊，其病因及发病机制尚不明确，临床上十分罕见，因此容易造成误诊和漏诊。现报告1例42岁宫颈癌肉瘤的病例资料，患者因接触性出血伴下腹痛收入院，盆腔磁共振成像示宫颈部体积明显增大，初步诊断为宫颈恶性肿瘤，遂行根治性全子宫切除+盆腔淋巴结切除+大网膜切除术，术后病理学明确诊断为宫颈癌肉瘤Ⅱb期。截至2024年3月2日，患者已行3次化疗，暂未发现复发及转移。宫颈癌肉瘤恶性程度高，临床表现无特异性，确诊主要依靠病理学检查和免疫组织化学检查，因此早识别、早治疗对改善患者的预后至关重要。

关键词: 癌肉瘤, 宫颈肿瘤, 诊断, 治疗, 病例报告

Abstract:

Cervical carcinosarcoma is a malignant tumor composed of malignant epithelial tissue and stromal components. Patients typically present with irregular vaginal bleeding and discharge. The etiology and pathogenesis of this condition remain unclear, and it is clinically very rare, making misdiagnosis and missed diagnosis common. This report presents a case of 42-year-old woman with cervical carcinosarcoma. The patient was admitted to the hospital due to contact bleeding accompanied by lower abdominal pain. Pelvic magnetic resonance imaging revealed a significant enlargement of the cervical region, with an initial diagnosis of cervical tumor. The patient subsequently underwent radical hysterectomy, pelvic lymphadenectomy, and omentectomy. Postoperative pathology confirmed the diagnosis of cervical carcinosarcoma, stage Ⅱb. As of March 2, 2024, the patient had undergone three rounds of chemotherapy, with no evidence of recurrence or metastasis detected so far. Cervical carcinosarcoma is highly malignant with nonspecific clinical manifestations, and definitive diagnosis relies mainly on pathological and immunohistochemical examinations. Therefore, early recognition and treatment are crucial for improving patient prognosis.

Key words: Carcinosarcoma, Uterine cervical neoplasms, Diagnosis, Therapy, Case reports

王晶, 王晓慧. 宫颈癌肉瘤一例并文献复习[J]. 国际妇产科学杂志, 2024, 51(5): 597-600.

WANG Jing, WANG Xiao-hui. Cervical Carcinosarcoma：A Case Report and Literature Review[J]. Journal of International Obstetrics and Gynecology, 2024, 51(5): 597-600.

参考文献 20

[1]	Shu X, Zhou Y, Wei G, et al. Cervical Carcinosarcoma: Current Understanding on Pathogenesis, Diagnosis, Management and Future Perspectives[J]. Clin Med Insights Oncol, 2021,15:11795549211056273. doi: 10.1177/11795549211056273.
[2]	Albert A, Lee A, Allbright R, et al. Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes[J]. J Gynecol Oncol, 2020, 31(3):e25. doi: 10.3802/jgo.2020.31.e25.
[3]	Lin Y, Chen H, Ye Z, et al. Synchronous carcinosarcoma of the uterine cervix with adenoid basal carcinoma and cervical intraepithelial neoplasia Ⅲ: A case report and literature review[J]. Pathol Res Pract, 2017, 213(5):570-573. doi: 10.1016/j.prp.2017.02.006.
[4]	刘宁. 宫颈癌肉瘤的研究进展[J]. 疑难病杂志, 2020, 19(9):963-967. doi: 10.3969/j.issn.1671-6450.2020.09.025.
[5]	Barker HE, Scott CL. Genomics of gynaecological carcinosarcomas and future treatment options[J]. Semin Cancer Biol, 2020, 61:110-120. doi: 10.1016/j.semcancer.2019.10.006. pmid: 31622660
[6]	Bansal S, Lewin SN, Burke WM, et al. Sarcoma of the cervix: natural history and outcomes[J]. Gynecol Oncol, 2010, 118(2):134-138. doi: 10.1016/j.ygyno.2010.04.021. pmid: 20541244
[7]	Kimyon Comert G, Turkmen O, Karalok A, et al. Therapy Modalities, Prognostic Factors, and Outcome of the Primary Cervical Carcinosarcoma: Meta-analysis of Extremely Rare Tumor of Cervix[J]. Int J Gynecol Cancer, 2017, 27(9):1957-1969. doi: 10.1097/IGC.0000000000001086. pmid: 28708788
[8]	Ribeiro B, Silva R, Dias R, et al. Carcinosarcoma of the uterine cervix: a rare pathological finding originating from mesonephric remnants[J]. BMJ Case Rep, 2019, 12(3):e227050. doi: 10.1136/bcr-2018-227050.
[9]	Wu YC, Yang CF, Hsu CN, et al. Intramural metastases of rectum from carcinosarcoma (malignant müllerian mixed tumor) of uterine cervix[J]. Clin Nucl Med, 2013, 38(2):137-139. doi: 10.1097/RLU.0b013e318266d4bd.
[10]	Li L, Huang W, Xue K, et al. Clinical and imaging features of carcinosarcoma of the uterus and cervix[J]. Insights Imaging, 2021, 12(1):142. doi: 10.1186/s13244-021-01084-5.
[11]	Roma AA. Mesonephric carcinosarcoma involving uterine cervix and vagina: report of 2 cases with immunohistochemical positivity For PAX2, PAX8, and GATA-3[J]. Int J Gynecol Pathol, 2014, 33(6):624-629. doi: 10.1097/PGP.0000000000000088. pmid: 25272303
[12]	Mariño-Noya A, Magallanes-Peláez N, Puga-González N, et al. Cervical carcinosarcoma, report of some cases and a literature review[J]. Int J Gynaecol Obstet, 2024, 164(2):795-796. doi: 10.1002/ijgo.15202.
[13]	Sharma NK, Sorosky JI, Bender D, et al. Malignant mixed mullerian tumor (MMMT) of the cervix[J]. Gynecol Oncol, 2005, 97(2):442-445. doi: 10.1016/j.ygyno.2005.01.022. pmid: 15863143
[14]	Mercado KE, Badiner NM, Wang C, et al. Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience[J]. Cancers(Basel), 2023, 15(19):4690. doi: 10.3390/cancers15194690.
[15]	Tsatsaris G, Fasoulakis Z, Koutras A, et al. Primary Cervical Carcinosarcoma: Report of a Rare Case[J]. Surg J(N Y), 2022, 8(3):e174-e178. doi: 10.1055/s-0042-1744152.
[16]	Homesley HD, Filiaci V, Markman M, et al. Phase Ⅲ trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2007, 25(5):526-531. doi: 10.1200/JCO.2006.06.4907. pmid: 17290061
[17]	Semczuk A, Colas E, Walczyna B, et al. Coexistence of homologous-type cervical carcinosarcoma with endometrioid-type G1 endometrial cancer: a case report with an immunohistochemical study[J]. Int J Clin Exp Pathol, 2014, 7(10):7191-7195.
[18]	Tseng CE, Chen CH, Chen SJ, et al. Tumor rupture as an initial manifestation of malignant mesonephric mixed tumor: a case report and review of the literature[J]. Int J Clin Exp Pathol, 2014, 7(3):1212-1217. doi: 10.1016/j.prp.2014.02.001.
[19]	Wright JD, Rosenblum K, Huettner PC, et al. Cervical sarcomas: an analysis of incidence and outcome[J]. Gynecol Oncol, 2005, 99(2):348-351. doi: 10.1016/j.ygyno.2005.06.021. pmid: 16051326
[20]	Zhu B, Liu Y, Li J, et al. Exceptional Response of Cryoablation Followed by Pembrolizumab in a Patient with Metastatic Cervical Carcinosarcoma with High Tumor Mutational Burden: A Case Report[J]. Oncologist, 2020, 25(1):15-18. doi: 10.1634/theoncologist.2019-0739. pmid: 31848313